ArticleJournal of vascular surgery. Venous and lymphatic disorders2025
Oral sirolimus therapy for patients with complex low-flow vascular malformations.
Article in Journal of vascular surgery. Venous and lymphatic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A pharmacovigilance study of sirolimus-associated adverse events in organ transplantation.Frontiers in immunology · 2026Article
- The characteristics and outcomes of vascular abnormalities involving limbs in children: a retrospective analysis of 35 cases.Frontiers in pediatrics · 2026Article
- Precision therapy demands precision delivery in the evolution of treatment for low-flow vascular malformations.Journal of vascular surgery. Venous and lymphatic disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe evidence on the efficacy and safety of sirolimus therapy in patients with low-flow vascular malformations (LFVMs) has indicated its potential benefit in extensive and complicated lesions. This study aimed to assess the efficacy and safety of oral sirolimus therapy on complex LFVM patients when standard treatment alone was inadequate.
methodsThis was a retrospective study of all adult patients with diagnosed LFVMs who were treated with oral sirolimus where standard therapy was inadequate in a single specialist center from May 1, 2016, to April 30, 2023. Demographic and clinical data including patient reported responses, visual analogue scores for pain and adverse effects, and quality of life (QoL) scores (Short Form-36) were reviewed.
resultsWe included 55 LFVM patients (14 with syndromic disease and 41 with nonsyndromic) with a median age of 41 years (range, 23-72 years). While on sirolimus, 32 patients (58.2%) experienced some improvement with a nonsignificant higher percentage of nonsyndromic patients experiencing some improvements (P = .6478). There was a nonsignificant improvement in the quality of life scores for physical problems, energy/fatigue, and pain. There was also a nonsignificant increase in anxiety and depression scores. There was a significant decrease in the lesion size (P = .0004). Two patients reported a cessation of cellulitis episodes, and eight patients reported a partial or complete reduction in bleeding from their malformation or rectal bleeding. The most common side effects reported were mouth ulcers (54.5%), fatigue (29.1%), headache (25.5%), gastrointestinal problems (25.5%), and rash (12.7%); only five patients (9.1%) did not report any side effects. No significant difference was found between the side effects reported by syndromic and nonsyndromic patients.
conclusionsOral sirolimus therapy was clinically effective and safe in patients with complex LFVMs when standard therapy alone was inadequate. Further studies with longer follow-up are needed to evaluate oral sirolimus therapy in LFVM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.